Last update 29 Jun 2024
Rocbrutinib
Last update 29 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms LP 168, LP-168, LP168 + [6] |
Target |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Structure
Molecular FormulaC42H51N9O5 |
InChIKeyOYJVFTNYBWVQHA-SANMLTNESA-N |
CAS Registry2485861-07-0 |
Related
13
Clinical Trials associated with RocbrutinibA Phase Ib Study to Assess Safety and Preliminary Efficacy of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-NHL
一项评估LP-168联合R-CHOP方案治疗初治B细胞淋巴瘤有效性和安全性的Ib期研究
[Translation] A Phase Ib study evaluating the efficacy and safety of LP-168 combined with R-CHOP in the treatment of previously untreated B-cell lymphoma
The Mass Balance Study of [14C]LP-168 in Chinese Healthy Subjects
100 Clinical Results associated with Rocbrutinib
Login to view more data
100 Translational Medicine associated with Rocbrutinib
Login to view more data
100 Patents (Medical) associated with Rocbrutinib
Login to view more data
100 Deals associated with Rocbrutinib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Mantle cell lymphoma refractory | Phase 2 | CN | 21 Feb 2023 | |
| B-Cell Malignant Neoplasm | Phase 1 | CN | 20 Dec 2023 | |
| Multiple Sclerosis | Phase 1 | CN | 10 May 2022 | |
| Neuromyelitis Optica | Phase 1 | CN | 10 May 2022 | |
| Chronic Lymphocytic Leukemia | Phase 1 | US | 19 Jul 2021 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | US | 19 Jul 2021 | |
| Follicular Lymphoma | Phase 1 | US | 19 Jul 2021 | |
| Hairy Cell Leukemia | Phase 1 | US | 19 Jul 2021 | |
| Mantle-Cell Lymphoma | Phase 1 | US | 19 Jul 2021 | |
| Marginal Zone B-Cell Lymphoma | Phase 1 | US | 19 Jul 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 68 | bdfwtidjlt(caualxdpac) = bsytfcyfrt uevfndihxt (hmkhlcwzxs ) | - | 11 Dec 2023 | |||
Phase 1 | - | ndxpljxjcs(logauatrvv) = gkkvicohxg gegrjdyxvi (nlkrpotqsv ) View more | - | 10 Dec 2023 | |||
Phase 1 | 43 | cgeggzpwfw(ifghbvgiqp) = bjregehkwn auevwtbqso (rrdhglprms ) | - | 09 Dec 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free